Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
treprostinil palmitil
- Development stage
- Phase 3
- Lead developer
- Insmed
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
Treprostinil palmitil is a hexadecyl ester prodrug of treprostinil, designed as an inhaled dry powder formulation for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)[2][5]. It is hydrolyzed in the lungs by endogenous esterases to release active treprostinil, a prostacyclin analog that acts as a vasodilator and inhibits platelet aggregation[2][3]. Treprostinil palmitil aims to provide sustained pulmonary delivery and prolonged therapeutic effect compared to other formulations. The drug is currently investigational and has not been approved for any indication[1][5]. Insmed is developing this formulation.
- Brand names
- TPIP
- Other names
- TPIPTPIStreprostinil hexadecyl ester
02
Targets
PTGIR (Prostanoid IP Receptor)PTGER2 (Prostaglandin E2 receptor EP2)PTGDR (Prostanoid DP1 receptor)
Beyond the preview
Go deeper on treprostinil palmitil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on treprostinil palmitil.